This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Rhythm Pharmaceuticals (RYTM) and Damora Therapeutics (DMRA)

Tipranks - Tipranks - Tue Jun 16, 6:04AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Incyte (INCY), Rhythm Pharmaceuticals (RYTM) and Damora Therapeutics (DMRA) with bullish sentiments.

Claim 55% Off TipRanks

Incyte (INCY)

Guggenheim analyst Michael Schmidt maintained a Buy rating on Incyte today and set a price target of $136.00. The company’s shares closed last Friday at $108.53.

According to TipRanks.com, Schmidt is a 5-star analyst with an average return of 28.1% and a 53.4% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, ArriVent BioPharma, Inc., and Monte Rosa Therapeutics. ;'>

Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $111.87, a 3.7% upside from current levels. In a report issued on June 8, TipRanks – Anthropic also upgraded the stock to Buy with a $114.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Rhythm Pharmaceuticals (RYTM)

Guggenheim analyst Seamus Fernandez reiterated a Buy rating on Rhythm Pharmaceuticals today and set a price target of $143.00. The company’s shares closed last Friday at $88.38.

According to TipRanks.com, Fernandez is a 5-star analyst with an average return of 24.1% and a 59.5% success rate. Fernandez covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Sagimet Biosciences, Inc. Class A, and Mineralys Therapeutics, Inc. ;'>

Currently, the analyst consensus on Rhythm Pharmaceuticals is a Strong Buy with an average price target of $137.62, representing a 57.0% upside. In a report released today, Needham also maintained a Buy rating on the stock with a $130.00 price target.

Damora Therapeutics (DMRA)

Guggenheim analyst Bradley Canino maintained a Buy rating on Damora Therapeutics today and set a price target of $40.00. The company’s shares closed last Friday at $20.78.

According to TipRanks.com, Canino is a 4-star analyst with an average return of 7.9% and a 41.7% success rate. Canino covers the Healthcare sector, focusing on stocks such as Bicara Therapeutics Inc., Janux Therapeutics Inc, and Syndax Pharmaceuticals. ;'>

Damora Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $43.14, a 101.5% upside from current levels. In a report issued on June 8, TD Cowen also initiated coverage with a Buy rating on the stock.

Read More on INCY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).